Text Size
271 studies found for:    "Multiple Sclerosis, Relapsing-Remitting"

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
"Multiple Sclerosis, Relapsing-Remitting"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed BG00012 Phase 2 Combination Study in Subjects With Multiple Sclerosis
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Relapsing-remitting;   Multiple Sclerosis
Intervention: Drug: BG00012
2 Terminated
Has Results 		Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Minocycline;   Drug: Placebo
3 Completed An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention:
4 Recruiting Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: GSK239512;   Drug: Placebo
5 Completed
Has Results 		A Study to Evaluate Rebif® New Formulation (IFN-beta-1a) in Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Rebif® New Formulation (IFN-beta-1a)
6 Active, not recruiting
Has Results 		A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: interferon beta-1a (Rebif®);   Biological: alemtuzumab
7 Recruiting Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: MEDI-551;   Drug: Placebo
8 Completed Safety and Efficacy Study of Daclizumab High Yield Process to Treat Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-remitting
Interventions: Biological: Daclizumab High Yield Process;   Other: placebo
9 Recruiting Melatonin in Relapsing-Remitting Multiple Sclerosis Patients
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Melatonin
10 Recruiting An Efficacy and Safety Study of BG00012 in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis
Interventions: Drug: Placebo;   Drug: BG00012
11 Completed CLARITY - Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (MS)
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Cladribine Tablets;   Other: Placebo
12 Recruiting Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention:
13 Withdrawn QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)
14 Completed A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-Remitting Multiple Sclerosis (MS)
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Rebif® 44 mcg three times per week subcutaneously (SubQ);   Drug: Avonex® 30 mcg once weekly intramuscularly (IM)
15 Completed
Has Results 		Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Interferon beta 1b (Betaseron, BAY86-5046)
16 Recruiting A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Part A: 100 mg/mL GSK2618960;   Drug: Part A: matching placebo;   Drug: Part B: Dose of GSK2618960 decided from Part A;   Drug: Part B: matching placebo;   Drug: Part C: Dose of GSK2618960 decided from Part A and B
17 Active, not recruiting Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Rebif (Interferon beta-1a)
18 Completed Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Natalizumab;   Drug: Placebo
19 Not yet recruiting Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: RNS60 125 ml;   Drug: RNS60 250 ml;   Drug: Interferon beta 1a
20 Recruiting A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: abatacept;   Drug: Placebo
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years